Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
24,817,325
-
Share change
-
-2,795,595
-
Total reported value
-
$168,176,092
-
Put/Call ratio
-
1000%
-
Price per share
-
$6.88
-
Number of holders
-
64
-
Value change
-
-$84,640,277
-
Number of buys
-
36
-
Number of sells
-
32
Institutional Holders of Silence Therapeutics plc - ADS (SLN) as of Q4 2024
As of 31 Dec 2024,
Silence Therapeutics plc - ADS (SLN) was held by
64 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,817,325 shares.
The largest 10 holders included
TCG Crossover Management, LLC, Siren, L.L.C., Redmile Group, LLC, Lombard Odier Asset Management (USA) Corp, MORGAN STANLEY, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, Nantahala Capital Management, LLC, Nextech Invest Ltd., and EVENTIDE ASSET MANAGEMENT, LLC.
This page lists
64
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.